(Q34293543)

1 August 2017

1 reference

title

The EGF receptor family as targets for cancer therapy (English)

1 reference

1 August 2017

J Mendelsohn

1

1 reference

1 August 2017

J Baselga

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

1 August 2017

1 reference

1 August 2017

volume

19

1 reference

1 August 2017

issue

56

1 reference

1 August 2017

page(s)

6550-6565

1 reference

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Serum-free cell culture: a unifying approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Receptor blockade with monoclonal antibodies as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Regulation of cell death protease caspase-9 by phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Induction of apoptosis in fibroblasts by c-myc protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Identification of heregulin, a specific activator of p185erbB2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

The biology of erbB-2/neu/HER-2 and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Regulation of signal transduction and signal diversity by receptor oligomerization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Tyrosine kinase inhibition: an approach to drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Expression Cloning of Human EGF Receptor Complementary DNA: Gene Amplification and Three Related Messenger RNA Products in A431 Cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Heregulin regulation of Akt/protein kinase B in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Apoptosis and the cell cycle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

G1 events and regulation of cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

1 reference

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Specificity within the EGF family/ErbB receptor family signaling network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Autocrine secretion and malignant transformation of cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

A monoclonal antibody to the human epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204082

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204082

1 reference

Dimensions Publication ID

1 August 2017

1011731995

0 references

1 reference